The effect of thyroid hormone therapy on muscle function, strength and mass in older adults with subclinical hypothyroidism - an ancillary study within two randomized placebo controlled trials
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
The effect of thyroid hormone therapy on muscle function, strength and mass in older adults with subclinical hypothyroidism - an ancillary study within two randomized placebo controlled trials. / Netzer, Seraina; Chocano-Bedoya, Patricia; Feller, Martin; Janett-Pellegri, Camilla; Wildisen, Lea; Büchi, Annina E.; Moutzouri, Elisavet; Rodriguez, Elena Gonzalez; Collet, Tinh Hai; Poortvliet, Rosalinde K.E.; Mc Carthy, Vera J.C.; Aeberli, Daniel; Aujesky, Drahomir; Westendorp, Rudi; Quinn, Terence J.; Gussekloo, Jacobijn; Kearney, Patricia M.; Mooijaart, Simon; Bauer, Douglas C.; Rodondi, Nicolas.
In: Age and Ageing, Vol. 52, No. 1, afac326, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The effect of thyroid hormone therapy on muscle function, strength and mass in older adults with subclinical hypothyroidism - an ancillary study within two randomized placebo controlled trials
AU - Netzer, Seraina
AU - Chocano-Bedoya, Patricia
AU - Feller, Martin
AU - Janett-Pellegri, Camilla
AU - Wildisen, Lea
AU - Büchi, Annina E.
AU - Moutzouri, Elisavet
AU - Rodriguez, Elena Gonzalez
AU - Collet, Tinh Hai
AU - Poortvliet, Rosalinde K.E.
AU - Mc Carthy, Vera J.C.
AU - Aeberli, Daniel
AU - Aujesky, Drahomir
AU - Westendorp, Rudi
AU - Quinn, Terence J.
AU - Gussekloo, Jacobijn
AU - Kearney, Patricia M.
AU - Mooijaart, Simon
AU - Bauer, Douglas C.
AU - Rodondi, Nicolas
N1 - Publisher Copyright: © 2023 The Author(s). Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Background: loss of skeletal muscle function, strength and mass is common in older adults, with important socioeconomic impacts. Subclinical hypothyroidism is common with increasing age and has been associated with reduced muscle strength. Yet, no randomized placebo-controlled trial (RCT) has investigated whether treatment of subclinical hypothyroidism affects muscle function and mass. Methods: this is an ancillary study within two RCTs conducted among adults aged ≥65 years with persistent subclinical hypothyroidism (thyrotropin (TSH) 4.60-19.99 mIU/l, normal free thyroxine). Participants received daily levothyroxine with TSH-guided dose adjustment or placebo and mock titration. Primary outcome was gait speed at final visit (median 18 months). Secondary outcomes were handgrip strength at 1-year follow-up and yearly change in muscle mass. Results: we included 267 participants from Switzerland and the Netherlands. Mean age was 77.5 years (range 65.1-97.1), 129 (48.3%) were women, and their mean baseline TSH was 6.36 mIU/l (standard deviation [SD] 1.9). At final visit, mean TSH was 3.8 mIU/l (SD 2.3) in the levothyroxine group and 5.1 mIU/l (SD 1.8, P < 0.05) in the placebo group. Compared to placebo, participants in the levothyroxine group had similar gait speed at final visit (adjusted between-group mean difference [MD] 0.01 m/s, 95% confidence interval [CI] -0.06 to 0.09), similar handgrip strength at one year (MD -1.22 kg, 95% CI -2.60 to 0.15) and similar yearly change in muscle mass (MD -0.15 m2, 95% CI -0.49 to 0.18). Conclusions: in this ancillary analysis of two RCTs, treatment of subclinical hypothyroidism did not affect muscle function, strength and mass in individuals 65 years and older.
AB - Background: loss of skeletal muscle function, strength and mass is common in older adults, with important socioeconomic impacts. Subclinical hypothyroidism is common with increasing age and has been associated with reduced muscle strength. Yet, no randomized placebo-controlled trial (RCT) has investigated whether treatment of subclinical hypothyroidism affects muscle function and mass. Methods: this is an ancillary study within two RCTs conducted among adults aged ≥65 years with persistent subclinical hypothyroidism (thyrotropin (TSH) 4.60-19.99 mIU/l, normal free thyroxine). Participants received daily levothyroxine with TSH-guided dose adjustment or placebo and mock titration. Primary outcome was gait speed at final visit (median 18 months). Secondary outcomes were handgrip strength at 1-year follow-up and yearly change in muscle mass. Results: we included 267 participants from Switzerland and the Netherlands. Mean age was 77.5 years (range 65.1-97.1), 129 (48.3%) were women, and their mean baseline TSH was 6.36 mIU/l (standard deviation [SD] 1.9). At final visit, mean TSH was 3.8 mIU/l (SD 2.3) in the levothyroxine group and 5.1 mIU/l (SD 1.8, P < 0.05) in the placebo group. Compared to placebo, participants in the levothyroxine group had similar gait speed at final visit (adjusted between-group mean difference [MD] 0.01 m/s, 95% confidence interval [CI] -0.06 to 0.09), similar handgrip strength at one year (MD -1.22 kg, 95% CI -2.60 to 0.15) and similar yearly change in muscle mass (MD -0.15 m2, 95% CI -0.49 to 0.18). Conclusions: in this ancillary analysis of two RCTs, treatment of subclinical hypothyroidism did not affect muscle function, strength and mass in individuals 65 years and older.
KW - levothyroxine
KW - muscle
KW - older people
KW - sarcopenia
KW - subclinical hypothyroidism
U2 - 10.1093/ageing/afac326
DO - 10.1093/ageing/afac326
M3 - Journal article
C2 - 36721961
AN - SCOPUS:85165568109
VL - 52
JO - Age and Ageing
JF - Age and Ageing
SN - 0002-0729
IS - 1
M1 - afac326
ER -
ID: 371281770